Blood Product Supply During COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Time frame
研究概览
简要总结
Data about the links between Coronavirus disease 2019(COVID-19) and the safety of blood products during the pandemic is inadequate. During the COVID-19 pandemic, high volumes of patients receiving blood products due to post-terminal surgical complications depleted stores for the entire hospital, resulting in surgeons unable to acquire emergent blood products. Data from this study can be used to develop a policy on how to handle blood shortage issues during this and future pandemics. Also, this data can be used to determine future policies on use of blood products from COVID-19-positive donors.
详细描述
- To identify the circumstances associated with observed delays in receiving blood products to use in emergent cases.
- Determine the cost/benefit of moribund patients receiving massive transfusion during the COVID-19 pandemic.
- Quantify COVID-19 diagnosis and complications in patients arriving with no indication of disease at index admission as relative to in hospital or blood product exposure.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •>_18 years of age Surgical patients treated at Methodist Dallas Medical Center(MDMC)
排除标准
- •<18 years of age Prisoners Pregnant women
结局指标
主要结局
Time frame
时间窗: 1 year
Dates of inadequate or delayed blood products for emergent cases during the timeframe of the COVID-19 pandemic (March 2020 to March 2021) to be compared relative to number of days or cases where no shortages were noted
次要结局
未报告次要终点